** Shares of WW International WW.O , also known as
WeightWatchers, rise 8.6% to $11.17 after Craig-Hallum upgrades
stock to "hold" from "sell"
** Craig-Hallum says it underestimated investor interest in
the GLP-1 medications for weight-loss made by Novo Nordisk
NOVOb.CO and Eli Lilly LLY.N
** WW's acquisition of Sequence in March gives it a foothold
in the GLP-1 market through a telehealth business that
prescribes these drugs
** Brokerage expects health insurers to partner with co in
the long-term to make the costly drugs widely available to meet
increasing demand
** Envisions revenue from co's clinical business to rise 3x
in FY24 from $30 mln in FY23, says brokerage, raising PT on
stock to $10 from $4
** Of 7 analysts covering stock, 3 rate it "buy", 3 "hold"
and 1 "sell"; median PT stands at $12.50
** As of last close, WW shares had gained 165.9% since March
6, before the announcement of Sequence's acquisition
(Reporting by Purvi Agarwal in Bengaluru)
((Purvi.Agarwal@thomsonreuters.com))